Journal
JOURNAL OF NUCLEAR MEDICINE
Volume 62, Issue 7, Pages -Publisher
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.120.245290
Keywords
-
Funding
- National Research Foundation (NRF) of Korea [NRF-2017R1A2B3012157, NRF-2018M3A9H3024850]
- Pioneer Research Center Program - Ministry of Science and ICT (MSIT) [2015M3C1A3056410]
- NRF - MSIT [NRF-2020R1C1C1012379]
- Basic Science Research Program through the NRF of Korea - Ministry of Education [NRF-2020R1I1A1A01070543]
- NRF of Korea - Korean government (MSIT) [2018R1A5A2024181]
- National Research Foundation of Korea [2018M3A9H3024850] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
The study suggests that the CRT-specific peptide can be used to image ecto-CRT during immunogenic cell death, enabling early prediction of treatment response and assisting in deciding whether to continue immunotherapy.
Surface-exposed calreticulin (ecto-CRT) is a well-known 'eat-me' signal exhibited by dying cells that contributes to their recognition and destruction by the immune system. We assessed the use of a CRT-specific binding peptide for imaging ecto-CRT during immunogenic cell death and its utility for the early prediction of treatment response. Methods: A synthetic CRT-specific peptide KLGFFKR (CRTpep) was labeled with fluorescein isothiocyanate or F-18 and characteristics of ecto-CRT was evaluated in colon cancer cell line in vitro and in vivo. Results: In vitro flow cytometry, immunofluorescence staining, and in vivo micro positron emission tomography imaging results showed that CRTpep detected pre-apoptotic cells treated with immunogenic drugs or radiation, but not those treated with the non-immunogenic drug or a non-therapeutic dose of immunogenic drug. Conclusion: The present results indicate that the CRT-specific peptide would enable the prediction of therapeutic response, thereby facilitating early decisions regarding the continuation or discontinuation of immunogenic treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available